Cargando…

Lasmiditan mechanism of action – review of a selective 5-HT(1F) agonist

Migraine is a leading cause of disability worldwide, but it is still underdiagnosed and undertreated. Research on the pathophysiology of this neurological disease led to the discovery that calcitonin gene-related peptide (CGRP) is a key neuropeptide involved in pain signaling during a migraine attac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clemow, David B., Johnson, Kirk W., Hochstetler, Helen M., Ossipov, Michael H., Hake, Ann M., Blumenfeld, Andrew M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288483/ https://www.ncbi.nlm.nih.gov/pubmed/32522164 http://dx.doi.org/10.1186/s10194-020-01132-3

Ejemplares similares

Characterization of binding, functional activity, and contractile responses of the selective 5‐HT(1F) receptor agonist lasmiditan
por: Rubio‐Beltrán, Eloísa, et al.
Publicado: (2019)

The Effect and Safety of 5-HT(1F) Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis
por: Gu, Ping, et al.
Publicado: (2021)

Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol
por: Tsai, Max, et al.
Publicado: (2020)

The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials
por: Tfelt-Hansen, Peer C., et al.
Publicado: (2012)

Short-term efficacy and safety of lasmiditan, a novel 5-HT(1F) receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis
por: Hou, Min, et al.
Publicado: (2020)

Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT(1) receptors
por: Edvinsson, Jacob C. A., et al.
Publicado: (2022)

The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020)

Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies
por: Smith, Timothy, et al.
Publicado: (2020)

Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience
por: Blumenfeld, Andrew, et al.
Publicado: (2023)

Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
por: Kudrow, David, et al.
Publicado: (2020)

Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
por: Shapiro, Robert E., et al.
Publicado: (2019)

Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system
por: Labastida-Ramírez, Alejandro, et al.
Publicado: (2020)

Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache
por: Rau, Jill C, et al.
Publicado: (2020)

Effect of Selective 5-HT6R Agonist on Expression of 5-HT Receptor and Neurotransmitter in Vascular Dementia Rats
por: Yu, Haining, et al.
Publicado: (2017)

[(18)F]F13640: a selective agonist PET radiopharmaceutical for imaging functional 5-HT(1A) receptors in humans
por: Courault, Pierre, et al.
Publicado: (2023)

5-HT(2) and 5-HT(7) receptor agonists facilitate plantar stepping in chronic spinal rats through actions on different populations of spinal neurons
por: Sławińska, Urszula, et al.
Publicado: (2014)

CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
por: Capi, Matilde, et al.
Publicado: (2021)

Synthesis and Biological Evaluation of Disubstituted Pyrimidines as Selective 5-HT(2C) Agonists
por: Kim, Juhyeon, et al.
Publicado: (2019)

5-HT1A agonists, 5-HT3 antagonists and benzodiazepines : their comparative behavioural pharmacology /
Publicado: (1991)

Lasmiditan: A New Promising Drug in Migraine
por: Prakash, Sanjay, et al.
Publicado: (2021)

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
por: MacGregor, E Anne, et al.
Publicado: (2022)

Anti-PTSD Effects of Hypidone Hydrochloride (YL-0919): A Novel Combined Selective 5-HT Reuptake Inhibitor/5-HT(1A) Receptor Partial Agonist/5-HT(6) Receptor Full Agonist
por: Liu, Wen-Gang, et al.
Publicado: (2021)

The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials
por: Doty, Erin G., et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine
por: Tsai, Max, et al.
Publicado: (2021)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Anti-aggressive effects of the selective high-efficacy ‘biased’ 5-HT(1A) receptor agonists F15599 and F13714 in male WTG rats
por: de Boer, Sietse F., et al.
Publicado: (2015)

A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
por: Clemow, David B, et al.
Publicado: (2017)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
por: Rizzoli, Paul B
Publicado: (2014)

Budget impact of lasmiditan for the acute treatment of migraine in the United States
por: Milev, Sandra, et al.
Publicado: (2021)

Distribution of 5-HT(3), 5-HT(4), and 5-HT(7) Receptors Along the Human Colon
por: Yaakob, Nor S, et al.
Publicado: (2015)

Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
por: Oswald, Jessica C, et al.
Publicado: (2018)

5-HT(1F) Receptor Agonist Ameliorates Mechanical Allodynia in Neuropathic Pain via Induction of Mitochondrial Biogenesis and Suppression of Neuroinflammation
por: Zhang, Long-Qing, et al.
Publicado: (2022)

Agonists and antagonists induce different palonosetron dissociation rates in 5-HT(3)A and 5-HT(3)AB receptors()
por: Lummis, Sarah C.R., et al.
Publicado: (2013)

A single channel mutation alters agonist efficacy at 5-HT(3)A and 5-HT(3)AB receptors
por: Thompson, A J, et al.
Publicado: (2013)

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
por: Knievel, Kerry, et al.
Publicado: (2019)

Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists
por: Yempala, Thirumal, et al.
Publicado: (2020)

Translating the promise of 5HT(4) receptor agonists for the treatment of depression
por: Murphy, Susannah E, et al.
Publicado: (2021)

Human 5–HT(4) and 5–HT(7) Receptor Splice Variants: Are they Important?
por: Coupar, Ian M, et al.
Publicado: (2007)

The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties
por: Beattie, David T., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fhe3nhllc27t1vrji7ru4dcsg9